HMT is a biotech venture founded in 2003, based on the research achievements attained at the Institute for Advanced Biosciences (IAB), Keio University, Japan. HMT provides capillary electrophoresis mass spectrometry-based metabolomics services for researchers from companies and public research institutions. HMT is currently working on the development of clinical tests that utilize biomarkers for objective assessment of specific diseases. The company was listed on TSE Mothers in December 2013, on the 10th anniversary of its founding.